Skip to main content

Advertisement

SpringerLink
Log in

Drug interactions with phenprocoumon and the risk of serious haemorrhage: a nested case–control study in a large population-based German database

  • Pharmacoepidemiology and Prescription
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

Phenprocoumon is the most frequently used vitamin K antagonist in Germany. The aim of this study was to estimate the risk of serious bleeding as a result of the use of drugs with potential interaction with phenprocoumon.

Methods

We conducted a nested case–control study in a cohort of 246,220 phenprocoumon users in the German Pharmacoepidemiological Research Database. Cases were patients hospitalised for haemorrhage of different kinds. Ten controls were matched to each case by health insurance, birth year and sex using incidence density sampling. Odds ratios (OR) with 95% confidence intervals (CI) of the risk of serious bleeding associated with combined use of phenprocoumon and potentially interacting drugs versus phenprocoumon alone were estimated using conditional logistic regression analysis. Our analyses considered multiple risk factors, such as bleeding history, other comorbidities or co-medication.

Results

Our study included 2,553 cases and 25,348 matched controls. An increased risk of bleeding was observed for the combined use of phenprocoumon and clopidogrel vs phenprocoumon use alone (OR: 1.83, 95% CI: 1.41–2.36). Antibiotic drugs associated with an increased risk of haemorrhage in the population of phenprocoumon users included the group of quinolones with ORs ranging from 2.74 (95% CI: 1.80–4.18) for ciprofloxacin to 4.40 (95% CI: 2.45–7.89) for levofloxacin, amoxicillin plus clavulanic acid (OR: 2.99, 95% CI: 1.39–6.42) and cotrimoxazole (OR 3.57, 95% CI: 2.36–5.40). Among non-steroidal anti-inflammatory drugs (NSAIDs), ketoprofen and naproxen were associated with the highest risks.

Conclusion

Significantly elevated risks of major bleeding were mainly observed for drugs with known pharmacodynamic interaction with phenprocoumon, and less for drugs with possible pharmacokinetic interaction.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Gasse C, Hollowell J, Meier CR, Haefeli WE (2005) Drug interactions and risk of acute bleeding leading to hospitalisation or death in patients with chronic atrial fibrillation treated with warfarin. Thromb Haemost 94(3):537–543

    PubMed  CAS  Google Scholar 

  2. Hollowell J, Ruigomez A, Johansson S, Wallander MA, Garcia-Rodriguez LA (2003) The incidence of bleeding complications associated with warfarin treatment in general practice in the United Kingdom. Br J Gen Pract 53(489):312–314

    PubMed  Google Scholar 

  3. Lindh JD, Holm L, Dahl ML, Alfredsson L, Rane A (2008) Incidence and predictors of severe bleeding during warfarin treatment. J Thromb Thrombolysis 25(2):151–159

    Article  PubMed  CAS  Google Scholar 

  4. Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D’Angelo A, Pengo V, Erba N, Moia M, Ciavarella N, Devoto G, Berrettini M, Musolesi S (1996) Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 348(9025):423–428

    Article  PubMed  CAS  Google Scholar 

  5. Van der Meer FJ, Rosendaal FR, Vandenbroucke JP, Briet E (1993) Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Arch Intern Med 153(13):1557–1562

    Article  PubMed  Google Scholar 

  6. Budnitz DS, Pollock DA, Weidenbach KN, Mendelsohn AB, Schroeder TJ, Annest JL (2006) National surveillance of emergency department visits for outpatient adverse drug events. JAMA 296(15):1858–1866

    Article  PubMed  CAS  Google Scholar 

  7. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, Farrar K, Park BK, Breckenridge AM (2004) Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 329(7456):15–19

    Article  PubMed  Google Scholar 

  8. Van der Hooft CS, Sturkenboom MC, Van Grootheest K, Kingma HJ, Stricker BH (2006) Adverse drug reaction-related hospitalisations: a nationwide study in The Netherlands. Drug Saf 29(2):161–168

    Article  PubMed  Google Scholar 

  9. Hein L (2009) Antikoagulantien und Thrombozytenaggregationshemmer. In: Schwabe U, Paffrath D (eds) Arzneiverordnungs-report 2009. Springer, Berlin, pp 381–395

    Chapter  Google Scholar 

  10. Ufer M, Svensson JO, Krausz KW, Gelboin HV, Rane A, Tybring G (2004) Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro. Eur J Clin Pharmacol 60(3):173–182

    Article  PubMed  CAS  Google Scholar 

  11. Ufer M (2005) Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. Clin Pharmacokinet 44(12):1227–1246

    Article  PubMed  CAS  Google Scholar 

  12. Meda Pharma (2009) Marcumar fachinformation www.fachinfo.de. Accessed 2 June 2010

  13. Beinema M, Brouwers JR, Schalekamp T, Wilffert B (2008) Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon. Thromb Haemost 100(6):1052–1057

    PubMed  CAS  Google Scholar 

  14. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G (2008) Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 133(6 Suppl):160S–198S

    Article  PubMed  CAS  Google Scholar 

  15. ABDA Datenbank (2009) Interaktionsmonographien. ABDA-Bundesvereinigung Deutscher Apothekerverbände. Accessed 5 December 2009

  16. Drugdex evaluations (2008) Micromedex healthcare series http://www.thomsonhc.com . Accessed 29 August 2008

  17. Harder S, Thurmann P (1996) Clinically important drug interactions with anticoagulants. An update. Clin Pharmacokinet 30(6):416–444

    Article  PubMed  CAS  Google Scholar 

  18. Delaney JA, Opatrny L, Brophy JM, Suissa S (2007) Drug drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding. CMAJ 177(4):347–351

    Article  PubMed  Google Scholar 

  19. Battistella M, Mamdami MM, Juurlink DN, Rabeneck L, Laupacis A (2005) Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors. Arch Intern Med 165(2):189–192

    Article  PubMed  CAS  Google Scholar 

  20. Glasheen JJ, Fugit RV, Prochazka AV (2005) The risk of overanticoagulation with antibiotic use in outpatients on stable warfarin regimens. J Gen Intern Med 20(7):653–656

    Article  PubMed  Google Scholar 

  21. Zhang K, Young C, Berger J (2006) Administrative claims analysis of the relationship between warfarin use and risk of hemorrhage including drug-drug and drug-disease interactions. J Manag Care Pharm 12(8):640–648

    PubMed  Google Scholar 

  22. Penning-van Beest FJ, Koerselman J, Herings RM (2008) Risk of major bleeding during concomitant use of antibiotic drugs and coumarin anticoagulants. J Thromb Haemost 6(2):284–290

    PubMed  CAS  Google Scholar 

  23. Penning-van Beest FJ, Erkens J, Petersen KU, Koelz HR, Herings R (2005) Main comedications associated with major bleeding during anticoagulant therapy with coumarins. Eur J Clin Pharmacol 61(5–6):439–444

    Article  PubMed  CAS  Google Scholar 

  24. Visser LE, Penning-van Beest FJ, Kasbergen AA, De Smet PA, Vulto AG, Hofman A, Stricker BH (2002) Overanticoagulation associated with combined use of antibacterial drugs and acenocoumarol or phenprocoumon anticoagulants. Thromb Haemost 88(5):705–710

    PubMed  CAS  Google Scholar 

  25. Visser LE, Penning-van Beest FJ, Kasbergen AA, De Smet PA, Vulto AG, Hofman A, Stricker BH (2002) Overanticoagulation associated with combined use of antifungal agents and coumarin anticoagulants. Clin Pharmacol Ther 71(6):496–502

    Article  PubMed  CAS  Google Scholar 

  26. Pigeot I, Ahrens W (2008) Establishment of a pharmacoepidemiological database in Germany: methodological potential, scientific value and practical limitations. Pharmacoepidemiol Drug Saf 17(3):215–223

    Article  PubMed  Google Scholar 

  27. Schink, T, Behr, S, Garbe E (2009) Externe Validierung von Verschreibungsdaten nichtsteroidaler Antirheumatika anhand des Arzneiverordnungsreports 54. Jahrestagung der Deutschen Gesellschaft für Medizinische Informatik, Biometrie und Epidemiologie (gmds), 9 September 2009

  28. Behr S, Andersohn F, Garbe E (2010) Risk of intracerebral hemorrhage associated with phenprocoumon exposure: a nested case-control study in a large population-based German database. Pharmacoepidemiol Drug Saf 19(7):722–730

    Article  PubMed  Google Scholar 

  29. Palareti G, Cosmi B (2009) Bleeding with anticoagulation therapy—who is at risk, and how best to identify such patients. Thromb Haemost 102(2):268–278

    PubMed  CAS  Google Scholar 

  30. Rothman KJ, Greenland S, Lash TL (2008) Case-control studies. In: Rothman KJ, Greenland S (eds) Modern epidemiology. Lippincott Williams & Wilkins, Philadelphia, pp 111–127

    Google Scholar 

  31. Bergk V, Gasse C, Schnell R, Haefeli WE (2004) Requirements for a successful implementation of drug interaction information systems in general practice: results of a questionnaire survey in Germany. Eur J Clin Pharmacol 60(8):595–602

    Article  PubMed  Google Scholar 

  32. Rote Liste (2010) Cumarin-(4-Hydroxy)-Derivate Rote Liste http://www.rote-liste.de. Accessed 2 June 2010

  33. Flockhart DA (2007) Drug interactions: cytochrome P450 drug interaction table. Indiana University School of Medicine http://medicine.iupui.edu/clinpharm/ddis/table.asp. Accessed 2 June 2010

  34. Multidisciplinary Medication Management Project (2001) Top ten dangerous drug interactions in long-term care AMDA annual meeting http://www.scoup.net/m3project/topten/. Accessed 2 June 2010

  35. Schelleman H, Bilker WB, Brensinger CM, Han X, Kimmel SE, Hennessy S (2008) Warfarin with fluoroquinolones, sulfonamides, or azole antifungals: interactions and the risk of hospitalization for gastrointestinal bleeding. Clin Pharmacol Ther 84(5):581–588

    Article  PubMed  CAS  Google Scholar 

  36. Penning-van Beest FJ, van Meegen E, Rosendaal FJ, Stricker BH (2001) Drug interactions as a cause of overanticoagulation on phenprocoumon or acenocoumarol predominantly concern antibacterial drugs. Clin Pharmacol Ther 69(6):451–457

    Article  PubMed  CAS  Google Scholar 

  37. Cheetham TC, Levy G, Niu F, Bixler F (2009) Gastrointestinal safety of nonsteroidal antiinflammatory drugs and selective cyclooxygenase-2 inhibitors in patients on warfarin. Ann Pharmacother 43(11):1765–1773

    Article  PubMed  CAS  Google Scholar 

  38. Knijff-Dutmer EA, Schut GA, van de Laar MA (2003) Concomitant coumarin-NSAID therapy and risk for bleeding. Ann Pharmacother 37(1):12–16

    Article  PubMed  CAS  Google Scholar 

  39. Buresly K, Eisenberg MJ, Zhang X, Pilote L (2005) Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction. Arch Intern Med 165(7):784–789

    Article  PubMed  CAS  Google Scholar 

  40. Johnson SG, Rogers K, Delate T, Witt DM (2008) Outcomes associated with combined antiplatelet and anticoagulant therapy. Chest 133(4):948–954

    Article  PubMed  CAS  Google Scholar 

  41. Schalekamp T, Klungel OH, Souverein PC, de Boer A (2008) Effect of oral antiplatelet agents on major bleeding in users of coumarins. Thromb Haemost 100(6):1076–1083

    PubMed  CAS  Google Scholar 

  42. Hansen ML, Sorensen R, Clausen MT, Fog-Petersen ML, Raunso J, Gadsboll N, Gislason GH, Folke F, Andersen SS, Schramm TK, Abildstrom SZ, Poulsen HE, Kober L, Torp-Pedersen C (2010) Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 170(16):1433–1441

    Article  PubMed  CAS  Google Scholar 

  43. Sorensen R, Hansen ML, Abildstrom SZ, Hvelplund A, Andersson C, Jorgensen C, Madsen JK, Hansen PR, Kober L, Torp-Pedersen C, Gislason GH (2009) Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet 374(9706):1967–1974

    Article  PubMed  CAS  Google Scholar 

  44. Demirkan K, Stephens MA, Newman KP, Self TH (2000) Response to warfarin and other oral anticoagulants: effects of disease states. South Med J 93(5):448–454

    PubMed  CAS  Google Scholar 

  45. Penning-van Beest FJ, Van Meegen E, Rosendaal FR, Stricker BH (2001) Characteristics of anticoagulant therapy and comorbidity related to overanticoagulation. Thromb Haemost 86(2):569–574

    PubMed  CAS  Google Scholar 

  46. Fischer HD, Juurlink DN, Mamdani MM, Kopp A, Laupacis A (2010) Hemorrhage during warfarin therapy associated with cotrimoxazole and other urinary tract anti-infective agents: a population-based study. Arch Intern Med 170(7):617–621

    Article  PubMed  CAS  Google Scholar 

  47. Carroll DN, Carroll DG (2008) Interactions between warfarin and three commonly prescribed fluoroquinolones. Ann Pharmacother 42(5):680–685

    Article  PubMed  Google Scholar 

  48. Arnold LM, Nissen LR, Ng TM (2005) Moxifloxacin and warfarin: additional evidence for a clinically relevant interaction. Pharmacotherapy 25(6):904–907

    Article  PubMed  Google Scholar 

  49. Elbe DH, Chang SW (2005) Moxifloxacin-warfarin interaction: a series of five case reports. Ann Pharmacother 39(2):361–364

    Article  PubMed  Google Scholar 

  50. Ellis RJ, Mayo MS, Bodensteiner DM (2000) Ciprofloxacin-warfarin coagulopathy: a case series. Am J Hematol 63(1):28–31

    Article  PubMed  CAS  Google Scholar 

  51. O’Connor KA, O’Mahony D (2003) The interaction of moxifloxacin and warfarin in three elderly patients. Eur J Intern Med 14(4):255–257

    Article  PubMed  Google Scholar 

  52. Vadlamudi RS, Smalligan RD, Ismail HM (2007) Interaction between warfarin and levofloxacin: case series. South Med J 100(7):720–724

    Article  PubMed  Google Scholar 

  53. Stroud LF, Mamdami MM, Kopp A, Bell CM (2005) The safety of levofloxacin in elderly patients on warfarin. Am J Med 118(12):1417

    Article  PubMed  Google Scholar 

  54. Bayer Schering Pharma (2011) Xarelto 10 mg Filmtabletten Fachinformation www.fachinfo.de. Accessed 15 February 2011

  55. Boehringer Ingelheim (2011) Pradaxa 110 mg Hartkapseln Fachinformation www.fachinfo.de. Accessed 15 February 2011

  56. Walenga JM, Adiguzel C (2010) Drug and dietary interactions of the new and emerging oral anticoagulants. Int J Clin Pract 64(7):956–967

    Article  PubMed  CAS  Google Scholar 

  57. McMahan DA, Smith DM, Carey MA, Zhou XH (1998) Risk of major hemorrhage for outpatients treated with warfarin. J Gen Intern Med 13(5):311–316

    Article  PubMed  CAS  Google Scholar 

  58. Shireman TI, Mahnken JD, Howard PA, Kresowik TF, Hou Q, Ellerbeck EF (2006) Development of a contemporary bleeding risk model for elderly warfarin recipients. Chest 130(5):1390–1396

    Article  PubMed  Google Scholar 

  59. White RH, Beyth RJ, Zhou H, Romano PS (1999) Major bleeding after hospitalization for deep-venous thrombosis. Am J Med 107(5):414–424

    Article  PubMed  CAS  Google Scholar 

  60. Limdi NA, Beasley TM, Baird MF, Goldstein JA, McGwin G, Arnett DK, Acton RT, Allon M (2009) Kidney function influences warfarin responsiveness and hemorrhagic complications. J Am Soc Nephrol 20(4):912–921

    Article  PubMed  CAS  Google Scholar 

  61. Hallevi H, Albright KC, Martin-Schild S, Barreto AD, Savitz SI, Escobar MA, Gonzales NR, Noser EA, Illoh K, Grotta JC (2008) Anticoagulation after cardioembolic stroke: to bridge or not to bridge? Arch Neurol 65(9):1169–1173

    Article  PubMed  Google Scholar 

  62. Tompkins C, Cheng A, Dalal D, Brinker JA, Leng CT, Marine JE, Nazarian S, Spragg DD, Sinha S, Halperin H, Tomaselli GF, Berger RD, Calkins H, Henrikson CA (2010) Dual antiplatelet therapy and heparin "bridging" significantly increase the risk of bleeding complications after pacemaker or implantable cardioverter-defibrillator device implantation. J Am Coll Cardiol 55(21):2376–2382

    Article  PubMed  Google Scholar 

  63. Oake N, Jennings A, Forster AJ, Fergusson D, Doucette S, van Walraven C (2008) Anticoagulation intensity and outcomes among patients prescribed oral anticoagulant therapy: a systematic review and meta-analysis. CMAJ 179(3):235–244

    Article  PubMed  Google Scholar 

  64. Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, Wells PS (2005) Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 165(10):1095–1106

    Article  PubMed  CAS  Google Scholar 

  65. Zu Schwabedissen CM, Mevissen V, Schmitz F, Woodruff S, Langebartels G, Rau T, Zerres K, Hoffmann R, Ortlepp JR (2006) Obesity is associated with a slower response to initial phenprocoumon therapy whereas CYP2C9 genotypes are not. Eur J Clin Pharmacol 62(9):713–720

    Article  Google Scholar 

  66. Bell CM, Stroud LF, Kopp A (2007) The safety of levofloxacin in patients on warfarin—reply. Am J Med 120(4):E15–E16

    Article  Google Scholar 

  67. Schneeweiss S, Avorn J (2005) A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol 58(4):323–337

    Article  PubMed  Google Scholar 

Download references

Acknowledgement

The authors are grateful to all SHIs that provided data for this study. Three of these are the Allgemeine Ortskrankenkasse (AOK) Bremen/Bremerhaven, the Deutsche Angestellten-Krankenkasse (DAK), and the Handelskrankenkasse (HKK).

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Bremen Institute for Prevention Research and Social Medicine (BIPS), University of Bremen, Achterstrasse 30, 28359, Bremen, Germany

    Kathrin Jobski, Sigrid Behr & Edeltraut Garbe

Authors
  1. Kathrin Jobski
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sigrid Behr
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Edeltraut Garbe
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jobski, K., Behr, S. & Garbe, E. Drug interactions with phenprocoumon and the risk of serious haemorrhage: a nested case–control study in a large population-based German database. Eur J Clin Pharmacol 67, 941–951 (2011). https://doi.org/10.1007/s00228-011-1031-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-011-1031-6

Keywords

Search

Navigation